IP Library Granted Patent US 11,613,534
Granted Patent B2
US 11,613,534 · App. 17/082,612 · Granted Mar 28, 2023

Small molecule activators of Tie-2

Inventor: John M. Janusz (West Chester, OH)
Assignee: EyePoint Pharmaceuticals, Inc.
C07D417/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,613,534
App. No.
17/082,612
Granted
Mar 28, 2023
Kind
B2
Abstract

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.

Claims (56)

1. A compound of the formula:

wherein:

A is alkylene that is unsubstituted or substituted, or a bond;

B is thiazole, which is unsubstituted or substituted;

C is thiophene, which is unsubstituted or substituted;

D is alkylene that is unsubstituted or substituted, or a bond;

E is phenyl, which is unsubstituted or substituted;

R 1 is hydrogen, an acyl group, an alkoxycarbonyl group, an amidine group, or an amide group;

R 2 is alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, any of which is unsubstituted or substituted, or hydrogen;

R 3a is alkylene that is unsubstituted or substituted, or a bond;

R 3b is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, any of which is unsubstituted or substituted, or hydrogen; and

R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, any of which is unsubstituted or substituted

or a pharmaceutically-acceptable salt or zwitterion thereof.

2. The compound of claim 1 , wherein:

A is a bond;

B is thiazole which is unsubstituted or substituted;

C is thiophene;

D is alkylene that is unsubstituted or substituted;

E is phenyl, which is unsubstituted or substituted;

R 1 is an acyl group or an alkoxycarbonyl group;

R 2 is alkyl that is substituted or unsubstituted, or hydrogen;

R 3a is alkylene that is unsubstituted or substituted;

R 3b is aryl or heteroaryl, any of which is unsubstituted or substituted; and

R 4 is alkyl that is substituted or unsubstituted.

3. The compound of claim 2 , wherein:

C is thiophene;

E is phenyl that is unsubstituted or substituted; and

R 1 is an alkoxycarbonyl group.

4. The compound of claim 3 , wherein:

B is a thiazole;

D is methylene;

R 3a is methylene; and

R 3b is aryl that is unsubstituted or substituted.

5. The compound of claim 4 , wherein:

B is a thiazole;

E is 4-substituted phenyl; and

R 3b is phenyl.

6. The compound of claim 5 , wherein R 1 is a methoxycarbonyl group.

7. The compound of claim 6 , wherein:

R 2 is methyl or hydrogen; and

R 4 is methyl.

8. The compound of claim 7 , wherein R 2 and R 4 are methyl.

9. The compound of claim 7 , wherein R 2 is hydrogen and R 4 is methyl.

10. The compound of claim 7 , wherein E is

wherein:

X is methyl or hydrogen;

m is 0 or 1;

n is 0, 1, or 2; and

R 5 is hydrogen, hydroxyl, methyl, ethyl, phenyl, para-toluyl, N-piperidinyl, N-piperazinyl, N-pyrrolidinyl, OR 6 , or N(R 6 ) 2 , wherein each R 6 is independently hydrogen, methyl, ethyl, n-propyl, i-propyl, or n-butyl.

11. The compound of claim 10 , wherein:

X is hydrogen;

m is 1;

n is 2; and

R 5 is hydroxyl.

12. The compound of claim 8 , wherein the compound is:

13. The compound of claim 9 , wherein the compound is:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2021
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 057448/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2021
From: JANUSZ, JOHN M.
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 055003/0399 →
Continuity (2)
Provisional Application 62927233 · Oct 29, 2019
Related Publication 20210147404A1 · May 20, 2021
Cited By (1)
US 12,187,715